Star Combo Pharma Limited

ASX:S66 Stock Report

Market Cap: AU$20.3m

Star Combo Pharma Past Earnings Performance

Past criteria checks 3/6

Star Combo Pharma has been growing earnings at an average annual rate of 0.5%, while the Personal Products industry saw earnings growing at 7.8% annually. Revenues have been declining at an average rate of 7% per year. Star Combo Pharma's return on equity is 2.2%, and it has net margins of 2.8%.

Key information

0.5%

Earnings growth rate

5.5%

EPS growth rate

Personal Products Industry Growth-25.2%
Revenue growth rate-7.0%
Return on equity2.2%
Net Margin2.8%
Last Earnings Update30 Jun 2024

Recent past performance updates

Star Combo Pharma's (ASX:S66) Robust Earnings Might Be Weaker Than You Think

Mar 02
Star Combo Pharma's (ASX:S66) Robust Earnings Might Be Weaker Than You Think

Recent updates

Star Combo Pharma Limited's (ASX:S66) 30% Share Price Surge Not Quite Adding Up

Aug 23
Star Combo Pharma Limited's (ASX:S66) 30% Share Price Surge Not Quite Adding Up

Star Combo Pharma (ASX:S66) Might Have The Makings Of A Multi-Bagger

Aug 13
Star Combo Pharma (ASX:S66) Might Have The Makings Of A Multi-Bagger

Star Combo Pharma Limited's (ASX:S66) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Jun 12
Star Combo Pharma Limited's (ASX:S66) 27% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio

Star Combo Pharma (ASX:S66) Is Doing The Right Things To Multiply Its Share Price

May 12
Star Combo Pharma (ASX:S66) Is Doing The Right Things To Multiply Its Share Price

Star Combo Pharma Limited's (ASX:S66) Shares May Have Run Too Fast Too Soon

Mar 20
Star Combo Pharma Limited's (ASX:S66) Shares May Have Run Too Fast Too Soon

Should Shareholders Have Second Thoughts About A Pay Rise For Star Combo Pharma Limited's (ASX:S66) CEO This Year?

Nov 21
Should Shareholders Have Second Thoughts About A Pay Rise For Star Combo Pharma Limited's (ASX:S66) CEO This Year?

Star Combo Pharma's (ASX:S66) Robust Earnings Might Be Weaker Than You Think

Mar 02
Star Combo Pharma's (ASX:S66) Robust Earnings Might Be Weaker Than You Think

Rock star Growth Puts Star Combo Pharma (ASX:S66) In A Position To Use Debt

Dec 24
Rock star Growth Puts Star Combo Pharma (ASX:S66) In A Position To Use Debt

Revenue & Expenses Breakdown

How Star Combo Pharma makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:S66 Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Jun 2426150
31 Mar 2426150
31 Dec 2325040
30 Sep 2325-240
30 Jun 2325-440
31 Mar 2324-540
31 Dec 2223-540
30 Sep 2223-340
30 Jun 2223-150
31 Mar 2224-550
31 Dec 2124-850
30 Sep 2126-850
30 Jun 2127-850
31 Mar 2130-350
31 Dec 2033150
30 Sep 2036160
30 Jun 2039060
31 Mar 2038-160
31 Dec 1937-260
30 Sep 1929-260
30 Jun 1922-260
31 Mar 1917-270
31 Dec 1812-380
30 Sep 1812-270
30 Jun 1811-260
30 Jun 1710220
30 Jun 169210
30 Jun 157000
30 Jun 145000

Quality Earnings: S66 has high quality earnings.

Growing Profit Margin: S66 became profitable in the past.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: S66 has become profitable over the past 5 years, growing earnings by 0.5% per year.

Accelerating Growth: S66 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: S66 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Personal Products industry (8.9%).


Return on Equity

High ROE: S66's Return on Equity (2.2%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies